Single fraction of accelerated partial breast irradiation in the elderly: Early clinical outcome by Kinj, Rémy
RESEARCH Open Access
Single fraction of accelerated partial breast
irradiation in the elderly: early clinical
outcome
Rémy Kinj1, Marie-Eve Chand1, Jocelyn Gal2, Mathieu Gautier1, Lucile Montagné1, Daniel Lam Cham Kee1
and Jean Michel Hannoun-Lévi1*
Abstract
Background: To analyze the clinical outcome of elderly women with early breast cancer who underwent accelerated
partial breast irradiation (APBI) based on a post-operative single fraction of multicatheter interstitial high dose–rate
brachytherapy (MIB).
Methods: A single institution retrospective cohort study was performed focusing on elderly patients (≥ 65 years old)
presenting a low-risk breast carcinoma treated by lumpectomy plus axillary evaluation followed by MIB. A
single fraction of 16 Gy was prescribed on the 100% isodose. Clinical outcome at 3 years was reported based
on local relapse free survival (3-y LRFS), specific survival (SS) and overall survival (OS). Acute (< 180 days after
APBI) and late toxicity were evaluated. Cosmetic results were clinically evaluated by the physician.
Results: Between January 2012 and August 2015, 48 women (51 lesions) were treated. Median age was 77.
7 years (range: 65–92) with a median tumor size of 12 mm (range: 3–32). Five patients (pts) presented an
axillary lymph node involvement (4 Nmic, 1 N1). Invasive ductal carcinoma was the most frequent histology
type (86.3%). With a median follow–up of 40 months (range: 36–42), no local relapse occurred while 1 pt.
developed axillary relapse (2.1%). The 3-y LRFS, SS and OS rates were 100%, 100% and 93.1% respectively.
Forty-five acute events were remained. The most frequent acute toxicity was grade (G) 1 hyperpigmentation
(26.7%), 3 pts. (6.3%) presented G3 acute toxicity (2 breast hematomas, 1 breast abscess). No ≥ G3 late toxicity was
observed while 15 late toxicities occurred (G1: 13 events - 86.7%) mainly breast fibrosis). The rate of excellent cosmetic
outcome was 76.4%.
Conclusion: We reported promising and encouraging clinical outcome of a post-operative single fraction of MIB ABPI
in the elderly. This approach leads to consider a sfAPBI as an attractive alternative to intra-operative radiation therapy
while all the patients will be good candidates for APBI in regards to the post-operative pathological report. More
mature results (number of patients and follow-up) are needed.
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Background
During the last half of century, breast cancer therapeu-
tics progressed steadily and rapidly. In the management
of localized breast cancers, total mastectomy has grad-
ually given way to conservative surgical treatments
followed by adjuvant radiotherapy. The conservative
therapeutic approach is now considered as a standard of
care for T1–2 breast cancer [1, 2]. However, the stand-
ard adjuvant radiotherapy schedule (25 to 30 fractions)
generates much transportation that can be difficult
mainly for elderly women. Even using hypofractionated
regimen (15 to 16 fractions) [3–5] in place of standard
schedule, adjuvant breast irradiation can alter the quality
of life and sometimes the adhesion to the treatment.
Furthermore, a higher number of transportations gener-
ates additional costs for health insurance.
Accelerated partial breast irradiation (APBI) appears
as a natural continuity in the process of therapeutic
de-escalation. American Society of Radiation Oncology
(ASTRO) and Groupe Européen de Curiethérapie of the
European Society for Radiotherapy and Oncology (GEC-
ESTRO) have considered that, in a well selected popula-
tion, described as “suitable” (ASTRO) and “low-risk”
(ESTRO), adjuvant APBI can be proposed [6, 7]. After
two decades of clinical research, APBI is now recognized
as an efficient and safe adjuvant treatment for low-risk
breast cancer [8, 9].
The aim of this study was to report the early clin-
ical outcome of APBI in the elderly with early breast




This is a single institution retrospective study including
elderly patients presenting with low-risk breast cancer
who underwent lumpectomy plus axillary evaluation
followed by a single fraction of high-dose rate (HDR)
MIB APBI. The patient cohort combined women en-
rolled in a prospective phase I/II trial (SiFEBI; Clinical.-
gov #NCT01727011, [10]) and patients previously
treated before the SiFEBI trial opening. Briefly, inclusion
criteria were as follows: elderly women 65 years and
older, histologically proven breast carcinoma with free
surgical margins, negative axillary evaluation. Patients
were excluded in case of: sarcoma or lymphoma hist-
ology, metastatic dissemination. Data were collected
from the Antoine Lacassagne Cancer Center institu-
tional database. All the patients treated out of the SiFEBI
trial, had the choice between adjuvant WBI and sfAPBI.
All APBI indications were validated by the local breast
oncologist committee. Patients treated outside of the
SiFEBI trial (Clinical.gov #NCT01727011) were carefully
selected and fully informed about the new irradiation
procedure (advantages and disadvantages) compared to
the standard protocol of external beam radiation therapy
currently used in our institution. All those patients
signed consent form before starting the treatment.
Treatments
Breast surgery
As previously described, axillary dissection concerned
Level I and II axillary lymph node area while sentinel
lymph node biopsy alone was also achieved with per-op-
erative exam and conversion to axillary dissection in
case of positive biopsy. Then, lumpectomy was per-
formed. Quality of margins was assessed by a per-opera-
tive pathological exam. Four to five clips were clamped
by the surgeon to mark the tumor bed before closing the
tumor bed cavity [11].
Brachytherapy
Brachytherapy was performed according to the GEC-
ESTRO Breast Cancer Working Group recommenda-
tions for MIB APBI [12]. As previously described,
vectors (Sharp Needles™; Elekta AB, Stockholm,
Sweden) were placed mainly intra-operatively by the
radiation oncologist using 1 to 3 planes in respect
with Paris system recommendations [11]. Two days
after the implant, a post implant CT (2.5 mm thick-
ness slice) was performed in order to delineate the
clinical target volume (CTV) based on clips and sur-
gical cavity (if visible) including a total safety margin
of about 2 cm (sum of the resection margin size and
“added” safety margins size) [13]. Then, the dose dis-
tribution was optimized manually (OncentraBrachy®;
Elekta, Sweden) by varying time and stop position of
the radioactive source. A single fraction of 16 Gy was
prescribed to the 100% isodose. This dose was calcu-
lated considering an α/β ratio of 3.4 Gy for breast
late toxicity and 4.6 for local control [14]. According
to the linear quadratic model, the equivalent dose at
2 Gy (EQD2) for a single fraction of 16 Gy is equal
to 53 Gy with a α/β = 4 Gy [15, 16]. Dose constraints
were as follow: D90% ≥ 105% of the prescribed dose,
D100% ≥ 75%, V100 > 95% of the CTV, V150 ≤ 40%,
V200 ≤ 15%; dose non-homogeneity ratio (DNR) ≤ 35%
[10]. For organ at risk (skin and thoracic wall), the
maximum skin-dose was < 75% of the prescribed dose
while the maximum rib dose was < 100% of the pre-
scribed dose.
Systemic therapy
Systemic therapies such as adjuvant chemotherapy and/
or hormonal treatments were dispensed according to the
protocols used in the Antoine Lacassagne Cancer
Center.
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Follow up
The radiation oncologist performed iterative monthly
post-brachytherapy clinics during 3 months (acute brachy-
therapy side effects). Then, clinical surveillance was per-
formed alternatively with the surgeon twice a year with a
yearly mammogram. Acute (< 180 days after treatment)
and late toxicities were evaluated by Common Termin-
ology Criteria for Adverse Event v3 (CTCAE.V3.0) [17].
Cosmetic evaluation was performed according to Harvard
criteria [18].
Statistical analysis
Description of the study population and of the different
investigated parameters was made using absolute and
relative frequencies for the qualitative data and summa-
rized using descriptive statistics such as median, extreme
for quantitative data. Survival time was defined between
the surgery date and the event date. Local relapse
free-survival (LRFS), regional relapse free-survival
(RRFS), specific (SS) and overall survivals (OS) were esti-
mated using the Kaplan-Meier method. Patients still
alive were censored at the date of last follow-up. Median
follow-up with 95% confidence intervals was calculated
by reverse Kaplan–Meier method. Data entry and data
management were performed on Ennov clinical® system
and were analyzed using R 3.2.2 for Windows®.
Results
Patient and tumor characteristics
Between January 2012 and August 2015, a total of 51 le-
sions from 48 patients (pts) were treated with a sfAPBI.
Among these patients, 26 were part of the SiFEBI trial
while 22 pts. were treated out of the phase II study.
Patient, tumor and treatment features are detailed in
Table 1. Patient median age was 77.7 years [range: 65–
92]. Most of patients were ECOG Performans Status
(PS) 0 (85%). The most frequent location was the upper
external quadrant (39.2%). Histological type was mainly
invasive ductal carcinoma (86.2%). The median tumor
size was 12 mm [range: 3–32] while, 4 pts. presented
with a microscopic node involvement (Nmic) and 1 pt.
was classified N1. The median surgical margin was
5 mm [range: 1–10]. One lesion was associated with
peri-neural invasion. All the tumors but three had posi-
tive hormonal receptor status while Her-2 status was
over-expressed in 9.8%.
Treatment characteristics
A median number of 11 vectors [range: 5–15] on 2
planes [range: 1–3] were implanted (depending on the
thickness and location of the target volume), mainly
intra-operatively (92.2%). The median time between sur-
gery and sfAPBI was 7 days [range: 1–63]. The median
CTV was 44 cc [range: 11–124]. The median V100%
Table 1 Patients, lesions and treatment characteristics
Patient features Number of
patients
% / (min – max)
Patients included in SiFEBI trial
Yes 26 54.2
No 22 45.8








Upper external quadrant 20 39.2
Upper internal quadrant 5 9.8
Lower internal quadrant 3 5.9
Lower external quadrant 3 5.9
Junction of external quadrant 6 11.8
Junction of internal quadrant 3 5.9
Junction of lower quadrant 3 5.9
Junction of upper quadrant 6 11.7
Periareolar 2 3.9










Invasive ductal carcinoma 44 86.3
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was 96% [range: 86–100] (Table 1). The median treated
volume was 42 cc [range: 10–124].
Oncological outcome
With a median follow–up of 40 months [range: 36–42],
no local relapse occurred while 1 pt. developed an axil-
lary relapse (2.1%). Three-year LRFS, RRFS and SS were
100%, 3-year OS was 93.1% [86.4–1] (Fig. 1).
Acute and late toxicity
Forty-five acute events were remained. The most fre-
quent acute toxicity was grade (G) 1 hyperpigmentation
(26.7%). Three pts. presented G3 acute toxicity (2 breast
hematomas, 1 breast abscess). No ≥G3 late toxicity was
observed while 15 late toxicities occurred (G1: 11 events
[80%]). G1 breast fibrosis and hypopigmentation of
puncture site were the most frequent late side effects.
The rate of excellent cosmetic outcome was 76.4%. A
breast asymmetry was noticed in 2 pts. (4%) (Table 2).
Discussion
APBI is now recognized as a validated irradiation option
for low-risk breast cancer [12]. The current challenge is
to deliver irradiation dose in the shortest treatment dur-
ation, in the most appropriate population. From a tech-
nical point of view, 2 different APBI approaches can be
proposed: Intraoperative irradiation (electron or
low-energy X photon [50 kV]) or postoperative irradi-
ation either with brachytherapy (multicatheter interstitial
Table 1 Patients, lesions and treatment characteristics
(Continued)
Patient features Number of
patients




Median Ki-67 (%) 10 (5–60)
Median surg. Marg.(mm) 5 (1–10)
Implant time
Intra operative 47 92.2
Post-operative 4 7.8
Median time interv. Surg./APBI (d) 7 (1–63)
Median number of vectors 11 (5–15)
Median number of planes 2 (1–3)
Median CTV (cc) 44 (11–124)
Median V100% (%) 96 (86–100)
Median V150% (%) 34 (23–48)
Median V200% (%) 12 (8–21)
Median DNR 0.35 (0.23–0.56)
Median time interv. Surg./APBI: median time between intervention and sfAPBI;
Median surg. Marg.: median surgical margins; DNR: dose




















Fig. 1 Specific and overall survival
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brachytherapy [MIB] / balloon devices) or external beam
irradiation (3D or Intensity modulated) [19]. Intraopera-
tive irradiation (IORT) allows the optimal reduction of
the treatment duration since the patient is irradiated
during the lumpectomy process. However, at least 15%
of patients are partially irradiated while the definitive
histology is not suitable for this treatment [20]. Conse-
quently, those patients need a post-operative whole
breast irradiation (WBI) while the intra-op APBI is con-
sidered as a “boost”. Post-operative irradiation does per-
mit treating only validated candidates for APBI due to
an appropriate definitive pathological report compatible
with APBI criteria while the number of transportation
remains significantly higher compared to IORT. Further-
more, MIB-APBI allows best target coverage [21]. In this
frame, a post-operative single fraction APBI appeared as
an attractive technical option by drastically reducing the
number of transportations and in the same time, allevi-
ating the treatment related constraints mainly for elderly
patients with frequent comorbidities [22].
In our study, after a median follow-up of 40 months,
no local relapse was observed while SS rate was 100%.
Two studies already reported oncological outcome after
a MIB sfAPBI. In the SiFEBI prospective phase II trial,
26 elderly patients were treated with a 16 Gy sfAPBI.
After a median follow-up of 37 months, there was no
local relapse [10]. Recently, Latorre et al. reported the
results of 20 pts. treated with a MIB sfAPBI of 18 Gy.
After a median follow-up of 20 months, there was no
local relapse [23]. Other teams investigated very hypo-
fractionnated APBI, based on different regimens (1 to 7
fractions in 1 to 2 consecutive days) and HDR irradi-
ation techniques (Per-operative and balloon devices)
[24–27]. The results of those studies (oncological out-
come and toxicities) are summarized in Table 3.
Regarding MIB sfAPBI side effects, we did not report
G ≥ 3 late toxicity confirming the safety of this approach
already reported by others (Table 3). However, Sacchini
et al. had to decrease the per-operative delivered dose
from 20 Gy to 18 Gy due to the unexpectedly high-rate
of acute toxicity.
Specifically for elderly patients presenting with a
low-risk positive hormonal status breast cancer, the
omission of adjuvant radiation therapy was suggested in
order to alleviate the treatment. In those phase III ran-
domized trials (Surgery + hormonal therapy with or
without adjuvant WBI), there was no significant differ-
ence in terms of overall survival between irradiated and
non-irradiated patients [28, 29]. However, there was a
significant over-risk of local recurrence for patient with-
out adjuvant breast irradiation. In elderly patients, the
impact on functional status must be taken in account in
treatment decision. The GERICO-O3 phase II trial
aimed to evaluate the impact on functional status of
MIB APBI in a cohort of 46 elderly women (median age:
74 years). Activity Daily Living (ADL) and Instrumental
Activity Daily Living (IADL) scales were evaluated before
and after ABPI. The scores remained unchanged at 6
and 12 months after APBI confirming no deleterious im-
pact of MIB APBI [30].
Conclusion
We reported promising and encouraging clinical out-
come of a post-operative single fraction of MIB ABPI in
the elderly. This approach leads to consider a sfAPBI as
an attractive alternative to intra-operative radiation ther-
apy while all the patients will be good candidates for
Table 2 Acute and late toxicity outcome









Breast pain 2 4.4
Breast hematoma 2 4.4




Breast hematoma 2 4.4
Breast infection 1 2.2
Total 3 6.7
Total number of events 45 100
Late
Grade 1
Breast fibrosis 4 26.7






Breast fibrosis 2 13.3




Puncture site hypopig.: Puncture site hypopigmentation
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APBI in regards to the post-operative pathological re-
port. SfAPBI allows to drastically reducing the number
of transportations and could benefit to the patients by
decreasing fatigue and to the society by lowering cost re-
lated to transportations. More mature results (number
of patients and follow-up) are needed to confirm the
results.
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